Author:
Bassetti Matteo,Poulakou Garyfallia,Giamarellou Helen
Publisher
Springer Science and Business Media LLC
Subject
Critical Care and Intensive Care Medicine
Reference37 articles.
1. FDA (2010) FDA drug safety communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm . Accessed 28 April 2014
2. FDA (2013) FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning. http://www.fda.gov/drugs/drugsafety/ucm369580.htm . Accessed 5 May 2014
3. Yahav D, Lador A, Paul M, Leibovici L (2011) Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 66:1963–1971
4. Cai Y, Wang R, Liang B, Bai N, Liu Y (2011) Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 55:1162–1172
5. Tasina E, Haidich AB, Kokkali S, Arvanitidou M (2011) Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 11:834–844
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献